Addimmune entered into a merger agreement for a business combination to acquire 10X Capital Venture Acquisition Corp. III from a group of shareholders in a reverse merger transaction.
The transaction is subject to regulatory approval, the approval of the proposed merger by 10X III?s and Addimmune?s shareholders, the expiration or termination of the applicable waiting period under the HSR Act, the Registration Statement becoming effective and the Internal Reorganization and the Distribution having been consummated in all material respects in accordance with the Separation Agreement. Listing approval for combined company shares on NYSE, NASDAQ or NYSE American. The boards of directors of Addimmune and 10X III have unanimously approved the proposed merger, which is expected to be completed Q1 2024. As of October 5, 2023, 10X announced transfer of its Class A ordinary shares and the Warrants or the Listed Securities from New York Stock Exchange to the NYSE American LLC and that the trading of its Listed Securities on the NYSE American will commence at market open on or about October 9, 2023 under the current ticker symbols, VCXB, VCXB WS and VCXB.U for the Class A Ordinary Shares, Warrants and Units, respectively.
Roth Capital Partners is serving as financial advisor to 10X III in connection with rendering a fairness opinion to 10X III?s board of directors regarding the transaction. J. David Stewart and Ryan Maierson of Latham & Watkins LLP is legal counsel to 10X III. William F. Mulholland II of DLA Piper LLP (US) is serving as legal counsel to Addimmune. Morrow & Co., LLC is acting as proxy solicitor to 10X. 10X will pay proxy solicitation fees of $15,000 to Morrow. Continental Stock Transfer & Trust Company is acting as transfer agent to 10X.